Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tozinameran - BioNTech/Pfizer

Drug Profile

Tozinameran - BioNTech/Pfizer

Alternative Names: BNT 162; BNT 162b2; Bnt-162b2; BNT162b2 vaccine; BNT162b2SA; COMIRNATY; COVID-19 Vaccine, mRNA - BioNTech/Pfizer; PF-07302048; Pfizer-BioNTech COVID-19 vaccine; Pfizer-BioNTech vaccine; SARS-CoV-2 RNA vaccine - BioNTech/Pfizer

Latest Information Update: 27 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech; University of Roma La Sapienza
  • Developer BioNTech; Pfizer; Pfizer Japan; Shanghai Fosun Pharmaceutical
  • Class COVID-19 vaccines; RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed COVID 2019 infections
  • Phase II SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 18 Mar 2024 BioNTech withdraws a phase I trial in COVID-19 (In Children, In Infants, Prevention) prior to enrollment (IM, Injection) (NCT05630352)
  • 07 Mar 2024 Launched for COVID-2019 infections (Prevention) in Germany (IM) (Prior to March 2024)
  • 07 Mar 2024 Launched for COVID-2019 infections (Prevention) in Turkey (Parenteral) (Prior to March 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top